Navigation Links
OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
Date:7/14/2008

ology studies. More information is available at http://www.oncogenex.ca.

Definitive Agreement to Merge

On May 28, 2008, Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS) and OncoGenex Technologies Inc., jointly announced the signing of a definitive agreement to merge the two companies. The combined company will operate as OncoGenex Pharmaceuticals, Inc. The proposed transaction received unanimous approval from the Boards of Directors of Sonus and OncoGenex, and is expected to be completed in the third quarter of 2008, subject to the satisfaction of certain conditions, including the approval of Sonus' and OncoGenex' shareholders and, in the case of OncoGenex, court approval under the arrangement provisions of the Canada Business Corporations Act. OncoGenex management believes that the completion of this SPA for OGX-011 will result in the release of 25% of the escrowed shares that will be issued to OncoGenex shareholders at the completion of the merger pursuant to the Escrow Agreement described in the Proxy Statement and related materials filed by Sonus with the SEC. A final determination of the satisfaction of the release conditions under the Escrow Agreement must be made by the Board of Directors of Sonus immediately following the merger.

Safe Harbor

This press release contains forward-looking statements, including statements concerning clinical trial results and the proposed merger between Sonus and OncoGenex. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All statements
'/>"/>

SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex increases economic interest in lead cancer drug OGX-011
2. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
3. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
4. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
5. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
6. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
7. Edison Pharmaceuticals Receives Commendation From the City of San Jose
8. GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg
9. Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems
10. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
11. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 The ability for ... culture that will allow individuals to perform at the ... important for employers looking to compete in this post–recession ... embracing this trend, as the sector increasingly focuses on ... company, which will have real results on the organization's ...
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
(Date:8/28/2014)... Calif. , Aug. 28, 2014  Armetheon, ... on developing novel mid- to late-stage cardiovascular drug ... million in its first round of financing. The ... Investments and Hercules Bioventures with participation from investors ... and pharmaceutical executive, Dr. Larry Hsu , ...
(Date:8/28/2014)... 27, 2014 Scientists, researchers, and technologists ... SPIE Laser Damage 2014 symposium. Marking its 46th ... lasers will run 14-17 September. The event is sponsored ... photonics . , The premier conference for basic and ... to optical materials will engage researchers and engineers from ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3
... flu is already tough, but it has become even harder in ... two antiviral drugs don,t slow it down anymore. Reporting their ... and Brigham Young move closer to understanding why not, and how ... changes. The two drugs, amantadine and rimantadine, are no longer ...
... Biosystems announced the release of its second generation of ... the company,s popular in vivo delivery product line: PEG-Liposome ... compatible for in vivo transfection of other negatively charged ... also offers custom encapsulation of target molecules into PEG-liposome ...
... Oct. 21 Sermo ( http://www.sermo.com ), the largest ... Report titled, " Physician Participation in the ESA REMS ... rates in the FDA-required Erythropoiesis-Stimulating Agents (ESAs) risk evaluation ... the results, 83% of Hematologists/Oncologists view the ESA REMS ...
Cached Biology Technology:Putting a bull's-eye on the flu: Detailing influenza's structure for drug targeting 2PEG-Liposome siRNA In Vivo Transfection Kit From Altogen Biosystems 2Sermo Report Indicates Possible Decline in Prescribing of Erythropoiesis-Stimulating Agents 2
(Date:8/29/2014)... Bend them, stretch them, twist them, fold them: modern ... extraordinary technological potential, whether as artificial skin or electronic ... use remains a challenge but a new way of ... could be a game-changer. , Previous success in ... on the use of precious gold and silver nanowires. ...
(Date:8/28/2014)... expansion of marine protected areas is needed to protect ... to investigators from the Wildlife Conservation Society and other ... saving the largest numbers of species, often at the ... ecological functions. , Many vital ecological functions ... also are food for millions of people. This ...
(Date:8/28/2014)... the University of Minnesota have developed an animal research ... for muscle regeneration research as well as studies of ... research is published in the current edition of the ... treatment for FSHD, which is thought by many to ... is an unusual genetic disorder because, unlike most genetic ...
Breaking Biology News(10 mins):Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2UMN researchers find animal model for understudied type of muscular dystrophy 2
... There are few things more irritating than a fly ... to the problem. They hang up a bunch of Roridula ... leaf,s hairs, the hapless pest is soon trapped by the ... story. Each R. gorgonias plant is home to a population ...
... model for studying the genetics of Angelman syndrome, a ... in one out of 15,000 births, has been developed ... Their research demonstrates that when a particular fruit ... behavioral dysfunctions similar to those experienced by humans whose ...
... Say the word "biofuels" and most people think of ... technology called gasification that,s getting a new look from ... and Iowa State University. By combining gasification with ... from a wide range of biomass, including distiller,s grain ...
Cached Biology News:Nothing stops an expert in the art of living 2Model for angelman syndrome developed by University of Texas at Austin biologists 2Turning waste material into ethanol 2
... is a serine/threonine phosphatase isolated from human ... the heterodimer of 60kDa (A) and 36kDa ... dephosphorylate the a-subunit of phosphorylase kinase. With ... substrate specificity and may play a regulatory ...
... Analysis Note: Assays in Tris buffer, ... in the glycine buffer system. Assays in ... 5X that of the glycine buffer system. ... powder containing Tris-citrate buffer salts Preparation Unit ...
... The ATP Monitoring Kit ... with high sensitivity and a ... bioluminescence technique, the assay measures ... animal cells over a concentration ...
... condenses and traps a wide variety of solvent vapors ... glass condensation flask (GCF400) allows for the collection of ... Rapid cooling time minimizes waiting period., Ultra ... solvents , Digital Display ...
Biology Products: